Ernexa Therapeutics (ERNAW) Research & Development (2020 - 2026)

Ernexa Therapeutics (ERNAW) has 7 years of Research & Development data on file, last reported at $1.9 million in Q1 2026.

• Quarterly Research & Development rose 46.29% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 million (up 6.89% YoY) and the FY2025 annual result came in at $4.2 million, down 9.73% from the prior year.
• Research & Development rose to $1.9 million in Q1 2026, from $676000.0 in the prior quarter.
• In the past five years, Research & Development ranged from a high of $5.0 million in Q3 2022 to a low of $676000.0 in Q4 2025.
• A 5-year average of $1.6 million and a median of $1.4 million in 2023 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2022 — Research & Development surged 232.86% — and 2023, when it sank 72.05%.
• Tracing ERNAW's Research & Development over 5 years: stood at $2.0 million in 2022, then slumped by 30.68% to $1.4 million in 2023, then retreated by 14.85% to $1.2 million in 2024, then plunged by 41.62% to $676000.0 in 2025, then soared by 183.28% to $1.9 million in 2026.
• The last three Research & Development figures came in at $1.9 million (Q1 2026), $676000.0 (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.